Singapore (SG)

An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression (2016) Wyszynski A, Hong CC, Lam K, Michailidou K, Lytle C, Yao S, Zhang Y, et al. Journal article No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing (2016) Easton DF, Lesueur F, Decker B, Michailidou K, Li J, Allen J, Luccarini C, et al. Journal article Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus (2016) Horne HN, Chung CC, Zhang H, Yu K, Prokunina-Olsson L, Michailidou K, Bolla MK, et al. Journal article Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs) (2016) Darabi H, Beesley J, Droit A, Kar S, Nord S, Marjaneh MM, Soucy P, et al. Journal article Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation (2016) Ghoussaini M, French JD, Michailidou K, Nord S, Beesley J, Canisus S, Hillman KM, et al. Journal article Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer (2016) Shi J, Zhang Y, Zheng W, Michailidou K, Ghoussaini M, Bolla MK, Wang Q, et al. Journal article Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry (2016) Zhao Z, Wen W, Michailidou K, Bolla MK, Wang Q, Zhang B, Long J, et al. Journal article Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium (2016) Muranen TA, Blomqvist C, Doerk T, Jakubowska A, Heikkila P, Fagerholm R, Greco D, et al. Journal article Look-Ahead Schemes for Nearest Neighbor Optimization of 1D and 2D Quantum Circuits (2016) Wille R, Keszocze O, Walter M, Rohrs P, Chattopadhyay A, Drechsler R Conference contribution, Conference Contribution Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma (2016) Crump M, Leppa S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, et al. Journal article